After months of speculation about a possible takeover of Mirati Therapeutics, Bristol-Myers Squibb has reached a deal to buy the company and its KRAS inhibitor Krazati in
Mirati Therapeutics chief executive David Meek has agreed to step down by mutual agreement with the company's board, to be replaced on a temporary basis by founder and for
Mirati Therapeutics’ hopes of an EU approval for its KRAS inhibitor Krazati in the EU have been thrown into disarray after the EMA’s human medicines committee rejected the
Two weeks after Amgen reported the top-line result of its CodeBreak-200 trial of Lumakras in lung cancer, the data has been presented in abstract form at ESMO, showing a 34% improvement in
BeiGene has claimed a second EU approval for PD-1 inhibitor tislelizumab in non-small cell lung cancer (NSCLC), opening the door to the first launches of the drug outside
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.